secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001193125-24-262556
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Pharma terminates COO Brendan Teehan without cause; CEO assumes duties
-----------------------------------------------------------------------------

- Brendan Teehan, EVP, COO and Head of Commercial, involuntarily terminated without Cause effective Nov 18, 2024.
- Teehan will remain a non-executive employee until Dec 31, 2024 to assist transition.
- CEO Catherine Owen Adams, with 30+ years pharma commercial experience, will assume his responsibilities until a successor is appointed.
- No successor has been named; search for replacement is underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524262556/0001193125-24-262556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312524262556/d98060d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer